Lin BioScience, Inc. (TPEX:6696)
161.00
0.00 (0.00%)
Aug 15, 2025, 2:59 PM CST
Lin BioScience Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
Net Income | -1,024 | -744.27 | -687.19 | -313.52 | -434.7 | -151.84 | Upgrade
|
Depreciation & Amortization | 21.73 | 20.05 | 17.93 | 11.16 | 4.39 | 4.08 | Upgrade
|
Other Amortization | 0.43 | 0.16 | - | - | - | - | Upgrade
|
Loss (Gain) From Sale of Assets | - | - | - | - | -0.22 | - | Upgrade
|
Stock-Based Compensation | 700.07 | 291.06 | 115.15 | 44.39 | 8.91 | 0.93 | Upgrade
|
Other Operating Activities | -903.28 | -639.81 | -378.32 | -105.16 | 105.77 | -22.4 | Upgrade
|
Change in Accounts Receivable | -0.13 | 25.07 | -25.02 | 1.46 | -1.48 | - | Upgrade
|
Change in Accounts Payable | -1.53 | 8.36 | 60.64 | 13.32 | 19.46 | -7.23 | Upgrade
|
Change in Other Net Operating Assets | 51.9 | 20.08 | -116.02 | -12.66 | 8.02 | -4.14 | Upgrade
|
Operating Cash Flow | -1,155 | -1,019 | -1,013 | -361.01 | -289.84 | -180.61 | Upgrade
|
Capital Expenditures | -3.87 | -5.82 | -1.97 | -22.38 | -2.12 | -0.57 | Upgrade
|
Sale of Property, Plant & Equipment | - | - | - | - | 0.51 | - | Upgrade
|
Sale (Purchase) of Intangibles | -1.66 | -1.53 | - | - | - | - | Upgrade
|
Investment in Securities | -987.69 | -3,612 | - | - | - | - | Upgrade
|
Other Investing Activities | 129.07 | 68.2 | 3.83 | -1.67 | 0.13 | 0.78 | Upgrade
|
Investing Cash Flow | -864.15 | -3,551 | 1.87 | -24.06 | -1.48 | 0.2 | Upgrade
|
Long-Term Debt Repaid | - | -14.63 | -11.86 | -5.53 | -2.91 | -2.83 | Upgrade
|
Net Debt Issued (Repaid) | -15.93 | -14.63 | -11.86 | -5.53 | -2.91 | -2.83 | Upgrade
|
Issuance of Common Stock | 751.02 | 98.38 | 622.41 | 511 | 31.23 | 915.26 | Upgrade
|
Other Financing Activities | 1,820 | 2,581 | 2,026 | 624.32 | - | 247.93 | Upgrade
|
Financing Cash Flow | 2,555 | 2,665 | 2,637 | 1,130 | 28.32 | 1,160 | Upgrade
|
Foreign Exchange Rate Adjustments | -150.32 | 132.64 | -10.14 | 93.66 | -22.41 | -4.85 | Upgrade
|
Net Cash Flow | 385.97 | -1,773 | 1,616 | 838.39 | -285.4 | 975.11 | Upgrade
|
Free Cash Flow | -1,158 | -1,025 | -1,015 | -383.4 | -291.96 | -181.18 | Upgrade
|
Free Cash Flow Per Share | -14.48 | -13.04 | -13.72 | -5.34 | -4.24 | -2.92 | Upgrade
|
Cash Interest Paid | 1 | 1 | 1.21 | 0.88 | 0.07 | 0.13 | Upgrade
|
Cash Income Tax Paid | - | -69.4 | -29.53 | -18.4 | -9.53 | -23.02 | Upgrade
|
Levered Free Cash Flow | -886.84 | -573.21 | -635.88 | -658.48 | -31.55 | 142.18 | Upgrade
|
Unlevered Free Cash Flow | -886.24 | -572.58 | -635.13 | -657.93 | -31.5 | 142.33 | Upgrade
|
Change in Working Capital | 50.25 | 53.51 | -80.39 | 2.12 | 26.01 | -11.37 | Upgrade
|
Updated Aug 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.